Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BioNTech lifts vaccine target to 2 bln doses

Published 01/11/2021, 11:27 AM
Updated 01/11/2021, 11:30 AM

BioNTech has lifted its target for vaccine production.

Pfizer’s German partner now aims to churn out around 2 billion doses this year.

That’s up from an earlier target of 1.3 billion.

The new goal comes as extra production lines come on stream.

BioNTech has also found ways to extract more doses from each vial of the product.

In a presentation Monday (January 11), the firm said it would use so-called ‘low dead space syringes’.

They allow it to extract six doses from each standard vial, instead of the usual five.

A new production site in Marburg, Germany, has also been acquired from Novartis.

It will become operational by the end of February, and have an annual capacity of 750 million doses.

Contractors who supply ingredients have also ramped up capacity.

BioNTech said it had shipped 32.9 million doses as of Sunday (January 10).

A spokeswoman said the firm had actually made 50 million by the end of last year.

But shipments were held back to avoid excess storage time.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.